DVAX

Investor Moves

Name	Value	Action	Change	Price	Current Price
George SorosSoros Fund Management $-24.1M ExitQ1 2026 $24M $15.52 $15.50
Ken GriffinCitadel Advisors $-4.0M ExitQ1 2026 $4M $15.52 $15.50
Paul Tudor Jones IITudor Investment $-2.9M ExitQ1 2026 $3M $15.52 $15.50
Steven CohenPoint72 $-1.4M ExitQ1 2026 $1M $15.52 $15.50
Jim SimonsRenaissance Technologies $-51.3M ExitQ1 2026 $51M $15.52 $15.50
Mario GabelliGAMCO Investors $-615.2K ExitQ1 2026 $615k $15.52 $15.50

Trade DVAX

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.

CEO: Ryan Spencer
IPO Date: Feb 19, 2004

Market Data

Open: $15.50
High: $15.50
Low: $15.50
Volume: 5.7M
Avg Volume: 3.2M
52W High: $15.73
52W Low: $9.20

Valuation

Market Cap: $1.8B
Enterprise Value: $1.9B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $60.2M
Revenue: $277.2M
Net Income: $27.3M
Cash: $95.9M
Debt: $254.4M

Events

EarningsFeb 19

EPS est. 0.08135 · actual 0.05